MXCT vs NVST · rev $38.6M vs P/E 56, rev $2.51B
MaxCyte Inc (MXCT) versus Envista Holdings Corp (NVST) — a side-by-side from cached financials, not a winner call.
MaxCyte Inc (MXCT) is a medical devices company listed on NASDAQ.
Envista Holdings Corp (NVST) is a medical instruments & supplies company listed on US.
Latest reported MXCT revenue for 2024-12-31 was $38.6M. Net income was -$41.1M. Revenue was down 6.4% from 2023-12-31 to 2024-12-31. MXCT currently screens at market cap $124.3M.
Latest reported NVST revenue for 2024-12-31 was $2.51B. Net income was -$1.12B. Revenue was down 2.2% from 2023-12-31 to 2024-12-31. NVST currently screens at market cap $3.72B and trailing P/E 55.8.
MXCT currently screens at market cap $124.3M. NVST currently screens at market cap $3.72B and trailing P/E 55.8.
Not investment advice. Open the MXCT and NVST stock pages for the full models.
Not investment advice.